Karo Pharma AB (publ) (KARBF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Karo Pharma AB (publ) (KARBF) with AI Score 46/100 (Weak). Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products. The company focuses on the Nordic region and Europe, with sales in approximately 90 countries. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Karo Pharma AB (publ) (KARBF) Healthcare & Pipeline Overview
Karo Pharma AB (publ) develops and markets a diverse portfolio of prescription and over-the-counter products, focusing on skin health, intimate health, and pain relief, primarily in Europe and the Nordic region. The company distributes its products through direct sales and a network of distributors, including online channels.
Investment Thesis
Karo Pharma presents a compelling investment case based on its diversified product portfolio and established presence in the European and Nordic pharmaceutical markets. With a market capitalization of $1.52 billion, the company benefits from a broad range of prescription and OTC products targeting various health needs. Growth catalysts include expanding its online sales channels and further penetrating existing markets. Key value drivers include consistent revenue from established brands and potential for new product launches. However, investors may want to evaluate the risks associated with regulatory changes and competition from larger pharmaceutical companies. The company's ability to maintain market share and innovate new products will be critical for sustained growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Karo Pharma operates in approximately 90 countries, demonstrating a broad international presence.
- The company's product portfolio includes both prescription and over-the-counter drugs, providing diversified revenue streams.
- Karo Pharma focuses on the European and Nordic markets, leveraging established distribution networks.
- The company's key product categories include skin health, intimate health, and pain relief, addressing significant consumer needs.
- Karo Pharma's market capitalization stands at $1.52 billion, reflecting its established position in the pharmaceutical industry.
Competitors & Peers
Strengths
- Diversified product portfolio.
- Strong presence in the Nordic region and Europe.
- Established distribution network.
- Experienced management team.
Weaknesses
- Reliance on specific geographic markets.
- Exposure to regulatory changes.
- Competition from larger pharmaceutical companies.
- Dependence on key brands.
Catalysts
- Upcoming: Potential for new product launches in the skin health and intimate health categories.
- Ongoing: Expansion of online sales channels to reach a broader customer base.
- Ongoing: Strategic partnerships and collaborations to enhance product development and market access.
Risks
- Potential: Increased competition from generic drug manufacturers.
- Potential: Changes in healthcare regulations affecting pricing and market access.
- Ongoing: Dependence on key brands and product lines.
- Potential: Product liability claims and recalls.
Growth Opportunities
- Expansion of Online Sales Channels: Karo Pharma can significantly boost revenue by expanding its online sales channels. The e-commerce market for pharmaceuticals is growing rapidly, offering direct access to consumers and reducing reliance on traditional distribution networks. Investing in digital marketing and e-commerce infrastructure can increase market reach and improve customer engagement. This strategy aligns with the increasing trend of online healthcare purchases and can drive substantial growth in the coming years. The global e-pharmacy market is projected to reach $177.79 billion by 2026.
- Penetration of Existing Markets: Karo Pharma has the opportunity to deepen its penetration in existing markets, particularly in Europe and the Nordic region. By increasing marketing efforts, expanding distribution partnerships, and launching new products tailored to local needs, the company can capture a larger share of these established markets. This strategy leverages existing infrastructure and brand recognition, reducing the risks associated with entering new geographic regions. Focused market penetration can lead to sustainable revenue growth and improved profitability.
- Strategic Acquisitions: Karo Pharma can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring smaller pharmaceutical companies with complementary products or established presence in new markets can accelerate growth and diversify revenue streams. Careful due diligence and integration are crucial for successful acquisitions. This strategy can provide access to new technologies, intellectual property, and distribution networks, enhancing Karo Pharma's competitive position and long-term growth prospects.
- New Product Development: Investing in research and development to create innovative new products is essential for sustained growth. Karo Pharma can focus on developing novel formulations, line extensions, and products addressing unmet medical needs. This strategy requires a strong R&D pipeline and a commitment to innovation. Successful new product launches can drive revenue growth, improve brand image, and enhance Karo Pharma's competitive advantage in the pharmaceutical market. Focus on areas like dermatology and women's health could yield high-growth opportunities.
- Partnerships and Collaborations: Karo Pharma can leverage partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to expand its capabilities and market reach. Collaborations can provide access to new technologies, expertise, and distribution channels. Strategic partnerships can also reduce the risks and costs associated with developing and commercializing new products. This strategy can accelerate innovation, improve market access, and enhance Karo Pharma's overall competitiveness in the pharmaceutical industry.
Opportunities
- Expansion into new geographic markets.
- Development of innovative new products.
- Strategic acquisitions.
- Increased online sales.
Threats
- Generic competition.
- Pricing pressures.
- Changes in healthcare regulations.
- Product liability claims.
Competitive Advantages
- Established brand recognition in the Nordic region and Europe.
- Diversified product portfolio across multiple therapeutic areas.
- Extensive distribution network.
- Strong relationships with pharmacies and retailers.
About KARBF
Karo Pharma AB (publ), founded in 1987 and headquartered in Stockholm, Sweden, is a pharmaceutical company focused on developing and marketing prescription drugs and over-the-counter (OTC) products. Originally named Karo Bio AB (publ), the company changed its name in March 2016 to Karo Pharma AB (publ). The company's product portfolio includes skin health products marketed under brands like Remescar, Locobase, Decubal, and indy beauty. It also offers intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brands, and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. Additionally, Karo Pharma provides pain, cough, and cold remedies under brands such as Paracet, Ibux, Mollipect, and Viruseptin. The company also markets prescription drugs, including Burinex, Centyl, Kaleorid, and Lithionit, alongside wellness products like nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare. Karo Pharma distributes its products in approximately 90 countries, primarily in Europe and the Nordic region, through a combination of direct sales organizations, a network of distributors, and online channels. This diversified product range and extensive distribution network position Karo Pharma as a key player in the European and Nordic pharmaceutical markets.
What They Do
- Develops and markets prescription drugs.
- Offers over-the-counter (OTC) products for pharmacies and retail sectors.
- Provides skin health products under various brand names.
- Markets intimate health products.
- Offers foot health products.
- Provides pain, cough, and cold remedies.
- Sells wellness products.
Business Model
- Develops and manufactures pharmaceutical products.
- Markets products through direct sales organizations and a network of distributors.
- Sells products online.
- Focuses on the European and Nordic markets.
Industry Context
Karo Pharma operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The market is driven by an aging population, increasing healthcare awareness, and the rising prevalence of chronic diseases. Karo Pharma competes with both large multinational corporations and smaller regional players. Key trends include the growing demand for OTC products, the increasing importance of online sales channels, and the need for continuous product innovation to maintain market share. The company's focus on the European and Nordic markets positions it well to capitalize on regional growth opportunities.
Key Customers
- Pharmacies
- Retail sector
- Consumers in Europe and the Nordic region
- Hospitals and healthcare providers
Financials
Chart & Info
Karo Pharma AB (publ) (KARBF) stock price: Price data unavailable
Latest News
No recent news available for KARBF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KARBF.
Price Targets
Wall Street price target analysis for KARBF.
MoonshotScore
What does this score mean?
The MoonshotScore rates KARBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christoffer Lorenzen
CEO
Christoffer Lorenzen serves as the CEO of Karo Pharma AB (publ). Information regarding his detailed career history, education, and previous roles is not available in the provided data. As the CEO, he is responsible for the overall strategic direction and operational management of the company. His leadership is crucial for driving Karo Pharma's growth and maintaining its competitive position in the pharmaceutical market.
Track Record: Information regarding Christoffer Lorenzen's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His performance as CEO will be a key factor in Karo Pharma's future success.
KARBF OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and regulatory oversight. These companies may also have limited operating history or be in early stages of development. Investors should conduct thorough due diligence before considering investments in this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower liquidity compared to exchange-listed stocks.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Less regulatory oversight.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal disputes.
- Understand the company's capital structure and ownership.
- Monitor trading volume and price activity.
- Established presence in the pharmaceutical market.
- Diversified product portfolio.
- Sales in approximately 90 countries.
- Focus on the European and Nordic regions.
- History of operations since 1987.
KARBF Healthcare Stock FAQ
What does Karo Pharma AB (publ) do?
Karo Pharma AB (publ) is a pharmaceutical company that develops and markets a range of prescription and over-the-counter (OTC) products. Its portfolio includes skin health, intimate health, foot health, and pain relief products, sold under various brand names. The company operates primarily in Europe and the Nordic region, distributing its products through direct sales, a network of distributors, and online channels. Karo Pharma aims to address diverse consumer health needs with its broad product offerings.
What do analysts say about KARBF stock?
AI analysis is pending for KARBF. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is currently unavailable. Investors should monitor for future updates and conduct their own independent research to assess the potential risks and rewards associated with investing in Karo Pharma AB (publ). Further analysis will provide insights into the company's financial performance and market outlook.
What are the main risks for KARBF?
Karo Pharma faces several risks, including competition from generic drug manufacturers, which could erode market share and pricing power. Changes in healthcare regulations could also impact the company's ability to market and sell its products. Additionally, the company is dependent on key brands and product lines, making it vulnerable to market shifts and consumer preferences. Product liability claims and recalls also pose a risk to Karo Pharma's reputation and financial performance. These factors should be carefully considered by investors.
How does Karo Pharma AB (publ) navigate regulatory approval processes?
Information regarding Karo Pharma AB (publ)'s specific FDA/EMA regulatory track record, pending approvals, and compliance strategy is not available in the provided data. However, as a pharmaceutical company, Karo Pharma must adhere to stringent regulatory requirements in each of the markets it operates in. Successfully navigating these processes is crucial for bringing new products to market and maintaining compliance with existing regulations. Investors should monitor the company's regulatory filings and announcements for updates on this front.
How does Karo Pharma AB (publ) manage patent expiration risks?
Information regarding Karo Pharma AB (publ)'s patent cliff exposure, biosimilar competition, and lifecycle management strategies is not available in the provided data. However, as a pharmaceutical company, Karo Pharma faces the risk of patent expirations on its branded products, which could lead to increased competition from generic alternatives. Effective lifecycle management strategies, such as developing new formulations or indications for existing products, are crucial for mitigating this risk. Investors should monitor the company's patent portfolio and pipeline for updates on this front.
What are the key factors to evaluate for KARBF?
Karo Pharma AB (publ) (KARBF) currently holds an AI score of 46/100, indicating low score. Key strength: Diversified product portfolio.. Primary risk to monitor: Potential: Increased competition from generic drug manufacturers.. This is not financial advice.
How frequently does KARBF data refresh on this page?
KARBF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KARBF's recent stock price performance?
Recent price movement in Karo Pharma AB (publ) (KARBF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for KARBF.
- Some information is not available in the provided data.